Tracking Troubled NDAs: New FDA Regs Mean Less Clarity for Investors

After an 11-year process, FDA is doing away with "approvable" and "not approvable" letters. . The new name ("complete response") gets rid of the negative connotations of "not approvable". But it is likely to create more confusion-and less transparency--for investors and the public.

By Cole Werble

It’s commonplace to hear new drug application sponsors bemoan delayed approval decisions from the Food & Drug Administration.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet